Fortress Biotech, Inc. (NASDAQ:FBIOP – Get Free Report) passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $16.15 and traded as low as $15.78. Fortress Biotech shares last traded at $16.01, with a volume of 23,560 shares traded.
Fortress Biotech Stock Down 1.2%
The company has a fifty day simple moving average of $17.62 and a 200-day simple moving average of $16.15.
Fortress Biotech Company Profile
Fortress Biotech, Inc is a biopharmaceutical company focused on developing and commercializing medicines for serious and underserved diseases. Its research and development activities span oncology, immunology, infectious diseases, rare diseases and dermatology, with programs developed internally and through a network of subsidiary companies and strategic partners.
The company’s portfolio has included biologic therapies, small-molecule medicines and gene therapies. Fortress has supported the development of products such as cosibelimab, an investigational monoclonal antibody targeting PD-L1, as well as dermatology treatments developed through its Journey Medical subsidiary.
Further Reading
- Five stocks we like better than Fortress Biotech
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
